| CVX |
Report |
Adjusted EPS |
BEAT |
pred ~$6.05 vs. cons $5.79 |
MEDIUM |
| CVX |
Report |
Revenue |
BEAT |
pred ~$64.5B vs. cons $61.97B |
MEDIUM |
| CVX |
Report |
Worldwide net oil-equivalent production (mboe/d) |
IN-LINE |
pred ~3,420 mboe/d vs. cons 3,400 mboe/d |
LOW |
| CVX |
Guide |
FY2026 production growth guidance |
UNCHANGED |
guide ~9% vs. cons ~8.5% (7-10% range) (FY2026) |
MEDIUM |
| CVX |
Guide |
Q3 2026 share buyback range |
BETTER |
guide ~$3.25B vs. cons $2.75B midpoint of $2.5-3B range (Q3 2026) |
LOW |
| CVX |
Guide |
FY2026 capex budget |
UNCHANGED |
guide ~$18.5B vs. cons $18-19B midpoint (FY2026) |
HIGH |
| CVX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.6% |
— |
LOW |
| CVX |
Return |
5-day cumulative residual |
-1.8% (FADE) |
Q2 beat is substantially a war-driven price spike (Brent ~$106 vs FY27 consensus already down ~10% YoY to $13.25 EPS), so even with a headline beat, analysts are likely to treat the quarter as low-quality/non-recurring given inventory/derivative timing noise and equity-crude one-time capture; as Iran de-escalation headlines persist and Brent reverts toward $89 by 4Q26, out-period estimates get trimmed, pulling the stock back down over the week despite the beat, consistent with the already-declining FY2027 EPS revision trend. |
MEDIUM |